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Abstract
Background: Mutant prevention concentration (MPC) is an alternative pharmacodynamic parameter that has been
used to measure antimicrobial activity and represents the propensities of antimicrobial agents to select resistant
mutants. The concentration range between minimum inhibitory concentration (MIC) and MPC is defined as mutant
selection window (MSW). The MPC and MSW parameters represent the ability of antimicrobial agents to inhibit the
bacterial mutants selected. This study was conducted to determine the MIC and MPC values of four antimicrobials
including ceftiofur, cefquinome, florfenicol and tilmicosin against 105 Riemerella anatipestifer isolates.
Results: The MIC50/MIC90 values of clinical isolates tested in our study for ceftiofur, cefquinome, florfenicol and tilmicosin
were 0.063/0.5、0.031/0.5、1/4、1/4 μg/mL, respectively; MPC50/ MPC90 values were 4/64、8/64、4/32、16/256 μg/mL,
respectively. These results provided information on the use of these compounds in treating the R. anatipestifer
infection; however, additional studies are needed to demonstrate their therapeutic efficacy.
Conclusion: Based on the MSW theory, the hierarchy of these tested antimicrobial agents with respect to selecting
resistant subpopulations was as follows: cefquinome > ceftiofur > tilmicosin > florfenicol. Cefquinome was the drug that
presented the highest risk of selecting resistant mutant among the four antimicrobial agents.
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Background
Riemerella anatipestifer has been one of the most
troublesome etiological agents and causes heavy loss in
duck industry. It occurs worldwide, especially in Southeast
Asia [1]. The existence of R. anatipestifer infection symp-
toms observed is characterized by fibrinous pericarditis,
perihepatitis, airsacculitis, caseous salpingitis, and meningi-
tis. To date, at least twenty-one serotypes of R. anatipesti-
fer have been identified and little cross-immunoprotection
among serotypes was reported [2]. People have been
making great efforts to find new strategies to prevent or
control R. anatipestifer infection, since much work has
been done concentrating on the identification of factors
associated with virulence [1, 3, 4] and immunogenic
characterization based on outer membrane protein A in
recent years [5–7]. Even so, chemotherapy is still a major
approach in the treatment of R. anatipestifer infection
because of the complex immunology situation currently. Due
to the concern of high incidence of Riemerella anatipestifersis
and increasingly severe drug resistance or reduction of sus-
ceptibility, obtaining new treatment information and promis-
ing results with antimicrobial agents seems necessary [8–10].
Ceftiofur (β-lactam), cefquinome (β-lactam), florfenicol
(phenicol), and tilmicosin (macrolide) belong to three
families of antimicrobial agents and were developed for
exclusive use in animals. They have exhibited remarkable
antibacterial effects against diverse microorganisms since
being introduced, although resistance to those drugs
mentioned above has also been reported [11–14]. The
escalating resistance of R. anatipestifer field strains and
concerns over animals as putative reservoirs for anti-
microbial resistance genes force us to develop strategies to
make full use of the current drugs [8, 15].
Traditionally, the in vitro activity of antimicrobial
susceptibility is assessed by minimum inhibitory concen-
tration (MIC) or minimum bactericidal concentration
(MBC). The mutant prevention concentration (MPC)
concept is an alternative in vitro measurement of drug
susceptibility against the infecting pathogen, represent-
ing the drug concentration that prevents a population of
more than 1010 colony forming unit (CFU)/mL bacteria
from first mutation. Mutant selection window (MSW) is
defined as the concentration range between MIC and
MPC. The use of MPC and MSW is of aid in evaluating
the capacity and potency of antimicrobial agents for the
selection of resistant mutants [16].
Application of the MPC theory has been conducted in a
variety of organisms associated with human and animals
such as Escherichia coli [17], Salmonella enterica [18],
Staphylococcus aureus [19], Pseudomonas aeruginosa [20]
and Mannheimia haemolytica [21]. Essentially, the con-
cept of MPC has been historically and primarily estab-
lished for fluoroquinolones because of the resistance
mechanisms for antimicrobial agents and is applicable to
other classes under some restriction at present [22]. So
far, no published data of MPC have been available for
R.anatipestifer yet. Therefore, the purpose of this study
was to investigate the MPC of four antimicrobials against
105 R. anatipestifer isolates from China, providing advice
on rational use of these antimicrobial agents, and further
compare the potencies of these antimicrobials in selecting
resistant R. anatipestifer mutants.
Methods
Bacterial strains
During the period of 2008 to 2014, we randomly col-
lected R. anatipestifer isolates from the sick ducks or
geese that exhibited typical symptoms of Riemerella
anatipestifersis at the animal diagnostic departments of
Guangdong Province, China. The clinical cases were
provided by the farm owners who volunteered to par-
ticipate in the study. A total of 105 R. anatipestifer
clinical strains from ducks (n = 98) and geese (n = 7)
were obtained and used in this study. The bacteria
were identified by colony morphology and PCR method
for partial sequence of outer membrane protein A as
described previously [23]. The Animal Experimentation
Ethics Committee of South China Agricultural University
approved all experimental procedures. In principal, MPC
measurement should be performed against organisms
sensitive to antimicrobial agents (by MIC testing). Because
no critical susceptibility breakpoints were available for
these four compounds against R. anatipestifer, the resist-
ance breakpoints were tentatively interpreted according to
the Clinical and Laboratory Standards Institute (CLSI)
recommendation for E.coli or Pasteurella multocida [24].
Antimicrobial compounds
Antimicrobial agents exclusively approved for use in
animals including ceftiofur, cefquinome, florfenicol,
and tilmicosin were investigated in the present study.
These compounds were commercially purchased from
the manufactures in China. Stock solution of each anti-
microbial was prepared in proper solvent according to
the instructions of antimicrobial susceptibility testing
for bacteria isolated from animals and stored at −20 °C.
Escherichia coli ATCC 25922 and Staphylococcus
aureus ATCC 29213 were used as control strains.
MIC measurements
Minimum inhibitory concentrations were determined
by CLSI agar dilution methodology [24]. All studies
were carried out in triplicate. Briefly, each R. anatipes-
tifer isolate in logarithmic growth period was diluted
with 0.9 % saline to achieve a 0.5 McFarland standard
suspension, equal to the inoculum of 5 × 105 CFU/mL.
About 5 μL suspensions were inoculated on Mueller-
Hinton agar plates supplied with 5 % calf serum and
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containing antimicrobials (with a series of concentra-
tions between 64 and 0.004 μg/mL). Inoculated plates
were then incubated for 18 h at 37 °C in a constant
temperature incubator. The MIC was recognized as the
lowest antibiotic concentration showing no growth of
colony morphology.
MPC testing
The measurement of MPC was performed according to
a method previously described with slight modification
[21]. Briefly, three or four colonies were inoculated into
3 mL R. anatipestifer broth (tryptic soy broth contain-
ing 0.5 % yeast and 5 % new calf serum) and cultured
overnight. The next day, 100 μL R. anatipestifer sus-
pensions were transferred to 100 mL of R. anatipestifer
broth and shaken at the speed of 200 rpm under the
temperature of 37 °C overnight. The collected cultures
were concentrated by centrifugation at 4000 rpm for
20 min at 4 °C and then re-suspended in 5 mL of fresh
R. anatipestifer broth to produce ≥1010 CFU/mL sus-
pensions. Aliquots of 100 μL containing ≥1010 CFU/
mL were applied to R. anatipestifer agar plates incorp-
orating a series of antimicrobials with the concentra-
tions ranging from 512 to 1 ×MIC. Each plate was
prepared freshly, stored at 4 °C and used within 7 days.
Inoculated plates were then incubated as described
previously and observed for five days. MPC was taken
as the lowest antimicrobial concentration that allowed
no R. anatipestifer isolate growth. All MPC determina-
tions were carried out in triplicate for each isolate.
Results were identical and then used for data analysis.
The ratio of MPC to MIC was also calculated.
Results
MIC and MPC
A total of 98 R. anatipestifer isolates from ducks and 7
field strains from geese were tested against ceftiofur,
cefquinome, florfenicol and tilmicosin. MICs and MPCs
of antimicrobials assayed are shown in Table 1. MIC50/90
and MPC50/90 values are also shown. MPC values were
higher than MICs because of exposure to higher density
of bacterial inoculum. Following testing, MIC values of
ceftiofur ranged from ≤0.008 to 8 μg/mL, with MIC50
and MIC90 values of 0.063 μg/mL and 0.5 μg/mL
respectively; cefquinome had the MIC values ranging
between ≤0.008 to 16 μg/mL, with MIC50 of 0.031 μg/
mL and MIC90 of 0.5 μg/mL respectively; florfenicol had
the MIC values ranging from 0.125 to 16 μg/mL, with
MIC50 of 1 μg/mL and MIC90 of 4 μg/mL respectively;
tilmicosin had the MIC values ranging from 0.031 to
64 μg/mL, with MIC50 of 1 μg/mL and MIC90 of 4 μg/
mL respectively.
The corresponding MPC values of the four anti-
microbial agents assayed against 105 R. anatipestifer
isolates are also listed in Table 1. Following testing of
ceftiofur, MPC values ranged from 0.125 to ≥128 μg/
mL, with MPC50 and MPC90 values of 4 and 64 μg/mL
respectively; for cefquinome from 0.25 to ≥128 μg/mL
and 8 and 64 μg/mL respectively; for florfenicol from 1
to ≥128 μg/mL and 4 and 32 μg/mL respectively; for
tilmicosin from 0.25 to ≥128 μg/mL and 16 and 256 μg/mL
respectively.
Based on these MIC and MPC values, dosing to
achieve the MIC or MPC values (where possible) may
serve to inhibit susceptible bacterium or reduce the
selection of resistant mutants. The hierarchy of potency
Table 1 MIC/MPC distribution for four compounds with clinical isolates of R. anatipestifer (n = 105)
Drug Distribution of MIC and MPC values (μg/mL)
Concentrations ≤0.008 0.016 0.031 0.063 0.125 0.25 0.5 1 2 4 8 16 32 64 ≥128 MIC50/MIC90
MIC distribution
Ceftiofur 3 8 25 22 16 13 10 3 1 2 2 0.063/0.5
Cefquinome 28 22 15 6 12 9 5 3 3 1 1 0.031/0.5
Florfenicol 1 1 28 25 37 6 6 1 1/4
Tilmicosin 1 14 7 9 7 20 24 13 5 2 2 1 1/4
MPC distribution MPC50/MPC90
Ceftiofura 1 2 4 16 19 11 17 2 17 12 2 4/64
Cefquinomeb 2 1 4 14 17 24 14 10 9 8 8/64
Florfenicolc 11 21 21 22 9 10 3 1 4/32
Tilmicosind 2 1 7 4 10 22 10 10 5 31 16/256
MIC50 and MIC90 -the drug concentration at which 50 % or 90 % of the isolates are inhibited, respectively
MPC50 and MPC90-the drug concentration restricting the growth of mutant subpopulation for 50 % or 90 % respectively of the isolates tested
a Testing against 103 isolates
b Testing against 103 isolates
c Testing against 98 isolates
d Testing against 102 isolates
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for these tested agents based on MIC90 values was: ceftio-
fur = cefquinome > florfenicol = tilmicosin. The potency of
antimicrobial agents tested based on MPC90 values
followed the rank order: florfenicol > ceftiofur =
cefquinome > tilmicosin.
Mutant selection index calculations
The ratio of MPC to MIC was defined as selection index
(SI) [25]. The lower SI is, the better ability of antimicro-
bials to restrict the resistant mutant subpopulations.
Since working with a large population of R. anatipestifer
isolates is cumbersome, we calculated the mutant selec-
tion index (ratio of MPC to MIC) for each isolate so that
the capacity of selecting mutant enrichment for each
antimicrobial agent could be easily compared. The value
distribution for each antimicrobial agent was shown in
Table 2. In our investigation, MPC/MIC ratios were
slightly lower for florfenicol and higher for cefquinome.
The SI data indicated a better ability of florfenicol to
prevent non-susceptible mutant subpopulations and a
strong selective pressure of cefquinome to enrich R.
anatipestifer mutants.
Pharmacokinetics/Pharmacodynamics (PK/PD) calculations
We also selected MIC90 and MPC90 as the boundaries
of the mutant selective window [26]. Plasma pharma-
cokinetic data in ducks were available for cefquinome
and florfenicol [27, 28]. In conjunction with pharma-
cokinetic parameters of each compound in ducks, the vari-
ous PK/PD indices, including ratio of maximum plasma
concentration to MIC90 (Cmax/MIC90) or MPC90 (Cmax/
MPC90), ratio of area under the concentration-time curve
to MIC90 (AUC/MIC90) or MPC90 (AUC/MPC90), time
above MIC90 or MPC90 of the dosage interval ( %T>MIC90
or %T>MPC90), and time inside the mutant selection win-
dow of the dosage interval (%TMSW), are shown in Table 3.
%T >MIC serves as an important parameter for cephalo-
sporins and its value of cefquinome against R. anatipestifer
isolates was approximately 31.67 % by integrating the phar-
macokinetic values obtained from a intramuscular injection
of a dose of 5 mg/kg body weight [27]. No concentration
was observed to exceed the MPC90. According to the phar-
macokinetic data attained with a single dose of 30 mg/kg
body weight florfenicol intramuscularly [28], the values
determined for Cmax/MIC90, Cmax/MPC90, AUC24/MIC90,
AUC24/MPC90 were 1.62, 0.10, 18.21 h and 1.14 h for
florfenicol, respectively. All the concentrations of florfeni-
col in plasma were lower than MPC90 and %TMSW was
calculated to be approximately 21.67 %.
Discussion
Riemerella anatipestifer has been a problematic patho-
gen of commercial importance for several years and it is hard
to give the correct treatment measures. One possible reason
is poor cross immune protection among various serotypes;
another important reason may be due to the similarity of
clinical symptom between R. anatipestifer infection and E.
coli infection. In recent years, R. anatipestifer strains with
reduced susceptibility to antimicrobials have emerged as re-
ported in other’s study and our previous investigation [8, 23]
because of the use of antimicrobials in animals, which
reflects the necessity of searching for new compounds or
strategies to treat Riemerella anatipestifersis [8, 10, 23].
Maintaining the utility of antimicrobials in treating Riemer-
ella anatipestifersis seems to be a major challenge. As pro-
posed by other researchers, one of the strategies to tackle the
resistance problem is to reduce or prevent the emergence of
resistant mutants [19]. In human medicine, MPC values and
MPC/MIC ratios have been determined and studied exten-
sively in a large number of antimicrobial agents, involving
many kinds of organisms [29–32]. In the current study, we
first report the MPC values of four antimicrobials that were
exclusively developed for animals against 105 R. anatipestifer
field strains mainly isolated from South of China.
We selected several antimicrobial agents that were
approved exclusively and most commonly used in animals,
and also represented a wide range of antimicrobial agents.
To our surprise, up to 70 % strains had high MIC values of
enrofloxacin (≥2 μg/mL) and apramycin (≥64 μg/mL) (data
not shown). Based on the MIC data of the six compounds,
four antimicrobial agents tested in our study appeared to
have excellent in vitro activities against R. anatipestifer
strains, although they have different chemical structures
and action mechanisms. Previously, Blondeau et al. [21]
compared the MIC and MPC values of five antimicrobial
agents against bovine clinical isolates of Mannheimia
haemolytica. The rank order of potency that antimicro-
bials selected resistant mutants differed by using MIC and
MPC data. Such is the case for R. anatipestifer isolates.
The concentration zone between MIC and MPC was
recognized as MSW. Concentrations of antimicrobials
within MSW exerted a selective pressure for accumula-
tion of resistant strains. Ratio of MPC to MIC repre-
sented the ability of antimicrobial agents to block the
resistant mutant subpopulation. MPC, MSW and MPC/
Table 2 Distribution of different ratios of MPC to MIC for
clinical isolates of R. anatipestifer
Drug No. of isolates having different ratios of MPC to MIC
1 2 4 8 16 32 64 128 256 512 >512
Ceftiofura 1 3 1 8 6 22 25 14 8 6 9
Cefquinomeb 0 0 0 3 5 9 5 11 25 22 23
Florfenicol c 6 25 30 18 12 5 2 0 0 0 0
Tilmicosin d 1 5 15 20 8 17 14 10 5 3 4
a Testing against 103 isolates
b Testing against 103 isolates
c Testing against 98 isolates
d Testing against 102 isolates
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MIC ratio served as a guide for the potency of anti-
microbials in restricting resistant mutant selection. Based
on these, a large number of references tried to address the
issue of relationship between antimicrobials and bacteria.
Hansen et al. [20] thought ciprofloxacin was more active
than levofloxacin in selecting resistant Pseudomonas aeru-
ginosa amplification. By determining the MPC of three
quinolones against 100 clinical Streptococcus pneumo-
cocci, moxifloxacin seemed to exhibit more excellent anti-
mutant ability than levofloxacin and gemifloxin [33].
Wang et al. [34] tested the MPC of three quinolones
against Campylobacter jejuni isolated from chicken and
assumed that enrofloxacin had the lowest MPC among the
three tested quinolones, thus enrofloxacin represented
a low selective pressure for selection of resistant sub-
populations. Briales et al. [35] provided the MPC values
of fluoroquinolone against E. coli isolates carrying
different plasmid-mediated resistant genes qnr and
harboring isogenic gyrA and parC substitutions, consid-
ering that qnr genes played a vital role in selecting one-
step resistant mutants. From our results, florfenicol
appeared to be a compound with excellent in vitro activity
against these R. anatipestifer strains collected from South
China, although some mechanism of R. anatipestifer
isolates resistant to florfenicol has been described in other
districts [36].
The ratio of MPC/MIC was slightly higher for ceftio-
fur and cefquinome among the four antimicrobials
tested (Table 2). Even two cephalosporins developed for
animals are only used in veterinary medicine, and they
are classified as critically important antimicrobials by
the WHO [37, 38], their use to treat great numbers of
animals in duck industry is to be strongly discouraged
because of prudent use guidelines. Similar conclusion
was also obtained for the therapy of R. anatipestifer
infection based on the theory of MPC and MSW. In
addition, both ceftiofur and cefquinome cannot be ad-
ministered orally because of poor absorption; unless
used prophylactically, which would be in strong contradic-
tion to prudent use guidelines, therefore the usefulness of
ceftiofur and cefquinome may probably be reduced in
duck production to a bare minimum. Although ceftiofur
has successfully cured the R. anatipestifer infection in a
previous report [39], it should not be the first choice
considering the wider MSW and severe drug resistance
situation. The MSW of cefquinome was wider than that of
ceftiofur. In other words, cefquinome has weaker ability of
preventing the selection of R. anatipestifer mutants than
ceftiofur. Comparing MSWs and MPC/MIC ratios of the
four antimicrobials, cefquinome seems to be the drug that
most easily selects resistant mutants.
MIC or MPC-based therapeutic protocols and PK/PD
indices for suppressing the enrichment of resistant
bacterial subpopulations have been proposed and
studied in various in vivo or in vitro models extensively
[40–43]. PK/PD parameters such as AUC/MIC, Cmax/
MIC and T >MIC relate closely with the effect of anti-
microbials. In our laboratory, pharmacodynamics on the
basis of MIC values for cefquinome have been well stud-
ied in mice, yellow cattle, pigs and dogs against a series
of microorganisms in recent years, involving E. coli, S.
aureus, P. multocida, Klebsiella pneumoniae as well as
Haemophilus parasuis [44–50]. These publications
clearly described the relationship between the dosing
schedules and the antimicrobial effectiveness. Also, the
ability of cefquinome to restrict the selection of E. coli
mutants was predicted in an in vivo model. The results
demonstrated that %T >MPC of >50 % was favorable to
block the resistant mutants [43]. By integrating our
results with the published pharmacokinetic data of
antimicrobials in ducks, serum drug concentrations of
cefquinome and florfenicol may fall within the MSW
and the high MPC values could hardly be attained albeit
these two drugs had excellent MIC values. As cephalo-
sporin exhibited time-dependent property, we applied
this approach in our study and the predicted T >MIC
was approximately 7.6 h (Table 3), which was lower than
that obtained previously using P. multocida in yellow
cattle [46], but slightly higher than that calculated using
canine E. coli [50]. In vivo antimicrobial efficacy of
cefquinome against R. anatipestifer should be further
addressed. Little is known on the PK/PD relationship of
florfenicol against R. anatipestifer. Until now, no killing
studies of ceftiofur and tilmicosin based on MIC or
MPC parameters of R. anatipestifer have been
conducted in ducks. So more work based on the MSW
theory should be performed for the use of antimicrobial
agents in ducks.








Cmax/MIC90 Cmax/MPC90 AUC24/MIC90 (h) AUC24/MPC90 (h) T >MIC90 (h) T >MPC90 (h) %TMSW
Cefquinomea 5, IM 9.38 23.78 18.76 0.15 47.56 0.37 ~7.6 0 31.67
Florfenicolb 30, IM 3.24 36.42 1.62 0.10 18.21 1.14 ~5.2 0 21.67
Cmax serum maximum concentration, AUC24h area under curve over a 24 h time period, MIC minimum inhibitory concentration, MPC mutant prevention
concentration, TMSW time inside the mutant selection window, IM intramuscularly
a based on data as published by Yuan et al
b based on data as published by EL-Banna
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Conclusions
This is the first study that described the MIC and MPC
values of four antimicrobial agents developed exclusively
for animals against R. anatipestifer isolates. Our study
may shed light on the future antimicrobial therapies for
treatment of R. anatipestifer infection. Further in vivo or
in vitro studies are required to confirm the efficacy
based on the MIC or MPC values. The mutant selection
window hypothesis suggests that cefquinome is least
likely to prevent the emergence of R. anatipestifer mu-
tants among the four antimicrobials.
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